985 Companies

Access all companies

Find technology partners quickly.

Spotfolio tracks over one million companies in technology industries.

There are 985 companies in the field of Biopharma on spotfolio that produce or deliver products, that utilize or research technologies or that are otherwise engaged in topics such as Clinical, Drug, Research, Patients, Therapeutic, Pharmaceutical, Development, Treatment, Phase .

Start-ups (152)

Early-stage companies (271)

Established companies (490)

The majority of these companies is located in the following countries.

United States (511)

United Kingdom (73)

China (46)

Canada (45)

Example Companies

Find companies in your area

Greenwich LifeSciences Greenwich LifeSciences, Inc.

established

Access

  • Technologies
  • Core data such as location, employees, revenues
  • Similar and peer companies
  • and more

Web Quotes

received treatment to date. The past trials consist of three Phase I clinical trials and one Phase IIb clinical trial. Encouraging Results In a prospective ...

randomized, single-blinded, placebo-controlled, multi-center (16 sites) Phase IIb clinical trial led by MD Anderson and completed in 2018, no recurrences ...

immune response, thereby providing longer term protection. In the Phase IIb and three Phase I clinical trials there were no reported serious adverse events ...

clinical trial partners, and finalizing a protocol towards commencing a Phase III clinical trial. Our Next Steps Greenwich LifeSciences is currently ...

clinical trial partners, and finalizing a protocol towards commencing a Phase III clinical trial.

Have Shown Both Safety and Efficacy VIEW HERE Statistically significant Phase IIb clinical trial data shows that after median 5 years of follow-up, breast ...

Greenwich LifeSciences plans to commence a Phase III clinical trial that is conservatively designed to reproduce the Phase IIb clinical trial results and to continue ...

Offering to fund the manufacturing of GP2 and the commencement of the upcoming Phase III clinical trial. The shares began trading on the Nasdaq Capital Market

Acticor Biotech Acticor Biotech SAS

established

Access

  • Technologies
  • Core data such as location, employees, revenues
  • Similar and peer companies
  • and more

Web Quotes

Acticor Biotech, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including stroke and pulmonary embolism, as part ...

of its first drug candidate ACT017 who has just successfully completed a phase 1 study in the healthy volunteer, confided to Simbec-Orion carrying out his ...

BIOTECH ANNOUNCES THAT THE EUROPEAN MEDICINES AGENCY CLEARS THE ROUTE FOR A PHASE II OF ITS ACT017 PRODUCT IN STROKE Paris, April 25th, 2018 – Acticor Biotech ...

Biotech, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including stroke and pulmonary embolism, has discussed ...

Read more February 5, 2018 Press Releases ACTICOR BIOTECH COMPLETED ITS PHASE I CLINICAL TRIAL WITH ACT017 ACHIEVING ITS SAFETY AND TOLERABILITY PRIMARY ...

Acticor Biotech, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including stroke and other thrombosis disorders like

2020 Press Releases Acticor Biotech Announces the Success of the First Phase of its ACTIMIS study with Glenzocimab In Patients with Acute Ischemic Stroke ...

the acute phase of thrombotic diseases, including acute ischemic stroke, today announced the completion of its ACTIMIS Dose Escalation Phase of Glenzocimab ...

standard of care in Patients with acute ischemic stroke. This Dose Escalation Phase was successfully […] Read more January 21, 2020 Press Releases ACTICOR ...

janvier 2020 – ACTICOR Biotech, société de biotechnologie en phase clinique impliquée dans la phase aiguë des maladies thrombotiques, y compris les accidents ...

AT €22,3M New financing will enable the company to expand in the US its phase II clinical trial ACTIMIS for its drug candidate glenzocimab (ACT017) in ...

Acticor Biotech, a clinical stage biotechnology company involved in the acute phase […] Read more November 5, 2019 Press Releases ACTICOR BIOTECH PARTNER

Eutilex Eutilex Co. Ltd.

early-stage

Access

  • Technologies
  • Core data such as location, employees, revenues
  • Similar and peer companies
  • and more

Web Quotes

Preclinical Phase I Phase II - hTERT Standard therapy-failed recurrent solid cancers Discovery Preclinical Investigator - Initiated Trial Phase I Phase II - ...

Preclinical Phase I Phase II - NY-ESO-1 Standard therapy-failed recurrent sarcoma Discovery Preclinical Investigator - Initiated Trial Phase I Phase II CAR-T ...

refractory B cell leukemia and B cell lymphoma Discovery Preclinical Phase I Phase II - Solid cancer specialized CAR-T GPC3 + IL-18, hepatocellular carcinoma ...

carcinoma and non-small cell lung cancer Discovery Preclinical Phase I Phase II Antibody - EU101 Fully humanized anti-human 4-1BB monoclonal antibody. ...

Preclinical Phase I Phase II - EU102 Agonistic anti-AITR antibody. Positive costimulatory signals on T cells. Discovery Preclinical Phase I Phase II - EU103 ...

Preclinical Phase I Phase II - EU900 4-1BB mAb-based, tumor antigen targeting bispecific antibodies. Discovery Preclinical Phase I Phase II

Access

  • Technologies
  • Core data such as location, employees, revenues
  • Similar and peer companies
  • and more

Web Quotes

STTR Phase I. Cold-Sensitive Mutants of Taq DNA Polymerase 4/1/00 - 9/30/01 $154,502 - National Institute of General Medical Sciences, SBIR Phase I. Toward ...

SBIR Phase II. Cold-Sensitive Mutants of Taq DNA Polymerase 8/1/02 - 7/31/05 $689,155 - National Institute of General Medical Sciences, SBIR Phase I. Reversible ...

SBIR Phase I. Blood Inhibition Resistant Mutants of Taq DNA Polymerase 3/8/05 - 3/6/06 $107,144 - United States Department of Agriculture, SBIR Phase I. ...

- 6/30/06 $78,160 - National Institute of General Medical Sciences, SBIR Phase II. Blood Inhibition Resistant Mutants of Taq DNA Polymerase 3/7/06 - 3/6/08 ...

3/6/08 $678,280 - United States Department of Agriculture, SBIR Phase II. Soil Inhibition Resistant Mutants of Taq DNA Polymerase 9/15/06 - 9/14/08 $290 ...

Forensics, 1/1/2009 - 12/31/2010 $200,621 - National Science Foundation, SBIR Phase I. Inhibition-Resistant DNA Polymerases and Other Improvements for Detection

Access

  • Technologies
  • Core data such as location, employees, revenues
  • Similar and peer companies
  • and more

Web Quotes

Philadelphia, PA, February 2-6, 2013. 8/1/2012: EBS awarded $750k on a Phase II SBIR grant by NIH NHGRI, "New Platform for Ionic Current Measurement with ...

via the Protein Nanopore Method" 5/24/2012: EBS awarded a $50k Phase I Option and $1M Phase II SBIR grant by the US Army, "Development of an In vitro Assay ...

Neurotoxin to Minimize Use of Whole Animal Testing" 3/1/2012: EBS awarded $167k Phase II SBIR grant by the NIH NINDS, "Encapsulated Lipid Bilayer Based Assay for ...

awarded $800k Phase II SBIR grant by the NIH NIGMS, "Nanopatch System for Next Generation Ion Channel Recordings" 5/27/2011: EBS awarded $100k Phase I SBIR grant ...

Awarded $168k Phase I SBIR Grant by NIH NIGMS, "Nanopore Based Methods for Enantiomer Differentiation" 5/25/2010: EBS Awarded $150k Phase I SBIR Grant by ...

Awarded $300k Phase II SBIR Grant by NIST, "AC Amplifier and System for Nanopore Based DNA Sequencing" 1/14/2009: EBS Awarded $70k Phase I SBIR Grant by

Use detailed technology terms.

Only spotfolio allows for searching with detailed technology terms, as we provide you with all topics that technology companies talk about.

Use Cases

Register now

Why Technology Scouting?

Technology scouting is the basis for your innovation management, identifies new technological developments as early as possible and protects you from disruptive business models.

Identify technology partners

Boost your market research

Look beyond major players

Build long and short lists

Collect technology leaders, providers, start ups and potential new partners in lists via simple tagging to take further steps with your team.